Publications by authors named "Jonathan Zalevsky"

Claim this Profile
N
NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.
Sairah Ahmed, John DiPersio, James Essell, Catherine Diefenbach, Miguel-Angel Perales, Jonathan Zalevsky

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Arlene O Siefker-Radtke, Robert A Huddart, Mehmet A Bilen, Arjun Balar, Daniel Castellano, Jonathan Zalevsky

Urol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
Jonathan I Silverberg, David Rosmarin, Raj Chovatiya, Thomas Bieber, Stephen Schleicher, Jonathan Zalevsky

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent patents in allergy and immunology: The interleukin-2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases.
Christie Fanton, Jonathan Zalevsky

Allergy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
Nizar M Tannir, Maria Nirvana Formiga, Konstantin Penkov, Nikolay Kislov, Aleksandr Vasiliev, Jonathan Zalevsky

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Jonathan Zalevsky

Eur Urol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Jonathan Zalevsky

J Immunother Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.
Christie Fanton, Richard Furie, Vishala Chindalore, Robert Levin, Isam Diab, Jonathan Zalevsky

J Transl Autoimmun· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
Anna Morena D'Alise, Guido Leoni, Maria De Lucia, Francesca Langone, Linda Nocchi, Jonathan Zalevsky

J Immunother Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.
Tanya O Robinson, Shweta M Hegde, Allison Chang, Achintyan Gangadharan, Sarai Rivas, Jonathan Zalevsky

J Clin Invest· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.
Nina Shah, Miguel-Angel Perales, Cameron J Turtle, Mitchell S Cairo, Andrew J Cowan, Jonathan Zalevsky

Future Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti, Jonathan Zalevsky

J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development.
Alex S Lee, Suchi Tiwari, Isabel Bishop, Vartan Matossian, Nicole Romaneschi, Jonathan Zalevsky

Front Pain Res (Lausanne)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents.
Caroline M Kopruszinski, Juliana Swiokla, Yeon Sun Lee, Edita Navratilova, Laurie VanderVeen, Jonathan Zalevsky

Cell Mol Neurobiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
Takahiro Miyazaki, Mekhala Maiti, Marlene Hennessy, Thomas Chang, Peiwen Kuo, Jonathan Zalevsky

J Immunother Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases.
Neha Dixit, Christie Fanton, John L Langowski, Yolanda Kirksey, Peter Kirk, Jonathan Zalevsky

J Transl Autoimmun· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Marlene Hennessy, Andrew Wahba, Kumar Felix, Mariella Cabrera, Maria Gabriela Segura, Jonathan Zalevsky

Int J Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering IL-2 to Give New Life to T Cell Immunotherapy.
Willem W Overwijk, Mary A Tagliaferri, Jonathan Zalevsky

Annu Rev Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab.
Joshua R Veatch, Naina Singhi, Brenda Jesernig, Kelly G Paulson, Jonathan Zalevsky

J Immunother Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Jonathan Zalevsky

Cancer Discov· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
Xue Ge, Jack E Henningfield, Suresh Siddhanti, Janet Jobes, Lin Lu, Jonathan Zalevsky

Pain Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.
Giulia Parisi, Justin D Saco, Felix B Salazar, Jennifer Tsoi, Paige Krystofinski, Jonathan Zalevsky

Nat Commun· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Meenu Sharma, Hiep Khong, Faisal Fa'ak, Salah-Eddine Bentebibel, Louise M E Janssen, Jonathan Zalevsky

Nat Commun· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys.
Wouter Korver, Mary Carsillo, Josh Yuan, Neeraja Idamakanti, Matthew Wagoner, Jonathan Zalevsky

J Pharmacol Exp Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Salah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, Cara Haymaker, Courtney W Hudgens, Jonathan Zalevsky

Cancer Discov· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis